Takahashi, Sho, Mizukami, Katsuyoshi, Yasuno, Fumihiko, Asada, Takashi

Background: Dementia with Lewy bodies (DLB) is a common type of dementia. It is difficult to make an initial diagnosis of DLB because of a variety of early symptoms, including psychosis-like and depressive states. In this study, we examined the characteristic depressive symptoms of the prestage of DLB and the efficacy and safety of somatotherapy […]

Szaniszlo, P., German, P., Hajas, G., Saenz, D. N., Kruzel, M., Boldogh, I.

Background: The pathomechanism of Alzheimer’s disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Abeta) and on Tau hyperphosphorylation.; Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin (CLN) on instrumental daily activities of AD patients. The potential molecular […]

Stevens, Alan B., Lancer, Kevin, Smith, Emily R., Allen, Lisa, McGhee, Richard

Caring for a family member with dementia is associated with unique stressors and burdens related to caregiving. Delivering interventions with proven efficacy to dementia caregivers remains a challenge because of the complexity of providing psychosocial support and skills training for caregivers within current models of formal healthcare services. This article focuses on implementation research and […]

Squitieri, Ferdinando, Orobello, Sara, Cannella, Milena, Martino, Tiziana, Romanelli, Pantaleo, Giovacchini, Giampiero, Frati, Luigi, Mansi, Luigi, Ciarmiello, Andrea

Purpose: Huntington disease (HD) mutation increases gain-of-toxic functions contributing to glutamate-mediated excitotoxicity. Riluzole interferes with glutamatergic neurotransmission, thereby reducing excitotoxicity, enhancing neurite formation in damaged motoneurons and increasing serum concentrations of BDNF, a brain cortex neurotrophin protecting striatal neurons from degeneration.; Methods: We investigated metabolic and volumetric differences in distinct brain areas between 11 riluzole-treated […]

Sommer, Oskar H., Aga, Olav, Cvancarova, Milada, Olsen, Inge C., Selbaek, Geir, Engedal, Knut

Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]

Sobów, Tomasz, Kłoszewska, Iwona, Flirski, Marcin, Liberski, Paweł

Background and Purpose: Cholinesterase inhibitors (ChEI) are currently the mainstream symptomatic treatment of patients with Alzheimer’s disease (AD). To this end, the response to the treatment with ChEI is clinically difficult to predict. Several demographic, clinical and biological variables have been proposed as pre-treatment predictors of long-term therapy efficacy. The aim of the study was […]

Snitz, Beth E., O'Meara, Ellen S., Carlson, Michelle C., Arnold, Alice M., Ives, Diane G., Rapp, Stephen R., Saxton, Judith, Lopez, Oscar L., Dunn, Leslie O., Sink, Kaycee M., DeKosky, Steven T.

Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]

Silver, Jonathan M., Koumaras, Barbara, Meng, Xiangyi, Potkin, Steven G., Reyes, Patricio F., Harvey, Philip D., Katz, Douglas I., Gunay, Ibrahim, Arciniegas, David B.

Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]

Sevilla, C., Jiménez Caballero, P. E., Alfonso, V.

Aim: To know whether caregivers of Alzheimer’s disease (AD) patients on donepezil treatment are more satisfied with the orally disintegrating tablet (ODT) formulation than with the film-coated tablets.; Patients and Methods: Multicenter, cross-sectional study of patients with probably AD by DSM-IV or NINCDS-ADRDA criteria, on monotherapy with donepezil, ODT or film-coated tablets. Satisfaction with treatment […]

Schmidt, Reinhold, Alf, Claude, Bancher, Christian, Benke, Thomas, Berek, Klaus, Dal-Bianco, Peter, Führwürth, Gerhard, Imarhiagbe, Douglas, Jagsch, Christian, Lechner, Anita, Rainer, Michael, Reisecker, Franz, Rotaru, Juliana, Uranüs, Margarete, Walter, Andreas, Winkler, Andreas, Wuschitz, Albert

We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]